Dianthus Therapeutics | MGTA - Equity Capital And Reserves



Dianthus Therapeutics reported $303.08M in Equity Capital and Reserves for its fiscal quarter ending in June of 2025.


Equity Capital And Reserves Change Date
Adcock Ingram Holdings ZAR 5.54B 131.19M Dec/2024
Alaunos Therapeutics USD 2.06M 661K Dec/2024
Avita Medical AUD 4.5M 19.42M Dec/2024
Celltrion KRW 17.14T 298.25B Mar/2025
Cspc Pharmaceutical CNY 32.26B 2.59B Dec/2024
Dianthus Therapeutics USD 303.08M 49.4M Jun/2025
Divis Laboratories Ltd 149.69B 12.52B Mar/2025
IQVIA Holdings USD 5.78B 199M Jun/2025
Kangmei Pharma CNY 7.73B 546.26M Jun/2025
Knight Therapeutics CAD 773.91M 11.11M Sep/2024
Laboratorios Farma EUR 574.72M 6.82M Jun/2025
Malin Corporation EUR 193.2M 75M Dec/2024
Medical Developments International AUD 55.33M 9.6M Dec/2024
Moderna USD 9.4B 667M Jun/2025
Neuren Pharmaceuticals AUD 363.9M 144.75M Dec/2024
Organigram Holdings CAD 385.5M 61.85M Jun/2025
Organon & Co USD 733M 191M Jun/2025
Pharma Mar EUR 201.53M 4.06M Jun/2025
Qiagen NV USD 3.51B 97.61M Jun/2025
Revvity USD 7.64B 29.74M Mar/2025
Sartorius EUR 2.66B 51.3M Jun/2025
Sino Biopharmaceutical CNY 31.96B 884.2M Dec/2024
Tectonic Therapeutic USD 283.77M 142.99M Jun/2025
Tilray USD 3.47B 5.16M Nov/2024
Viatris USD 15.57B 79.9M Jun/2025
Xeris Pharmaceuticals USD -19300000 10.32M Jun/2025
Zz Pientze Pharmaceu 14.65B 617.48M Jun/2025